Article info

Download PDFPDF

Original research
The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

Authors

  1. Correspondence to Ms Marisa O Peluso; mpeluso{at}surfaceoncology.com
View Full Text

Citation

Peluso MO, Adam A, Armet CM, et al
The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

Publication history

  • Accepted March 21, 2020
  • First published April 28, 2020.
Online issue publication 
April 28, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.